2型糖尿病合并非酒精性脂肪性肝病患者血清网膜素、视黄醇结合蛋白4和Ⅰ型原胶原氨基端前肽水平及意义分析*

doi:10.3969/j.issn.1672-5069.2022.06.011

摘要/Abstract

摘要： 目的探讨2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者血清网膜素、视黄醇结合蛋白-4(RBP4)和Ⅰ型原胶原氨基端前肽(PINP)水平变化及其临床意义。方法 2019年6月～2021年12月我院诊治的T2DM合并NAFLD患者102例(轻度39例,中度34例,重度29例)和T2DM患者98例,使用超声检查行脂肪肝分度,采用ELISA法检测血清网膜素、RBP4和PINP水平,应用受试者工作特征曲线(ROC)评估各指标诊断NAFLD严重程度的效能。结果 T2DM合并NAFLD患者血清网膜素和PINP水平分别为(45.4±12.4)ng/mL和(29.6±6.2)ng/mL,显著低于T2DM患者【分别为(68.3±15.6)ng/mL和(35.8±7.3)ng/mL,P＜0.05】,而血清RBP4水平为(26.6±5.1)mg/L,显著高于T2DM患者【(20.1±4.6)mg/L,P＜0.05】;重度NAFLD患者血清网膜素和PINP水平分别为(40.7±4.9)ng/mL和(25.8±3.7)ng/mL,显著低于中度患者【分别为(45.2±5.6)ng/mL和(29.9±4.0)ng/mL,P＜0.05】或轻度患者【分别为(49.1±6.2)ng/mL和(32.2±3.3)ng/mL,P＜0.05】,而血清RBP4水平为(30.3±3.0)mg/L,显著高于中度患者【(26.5±2.8)mg/L,P＜0.05】或轻度患者【(23.9±3.1)mg/L,P＜0.05】;联合血清网膜素、RBP4和PINP诊断T2DM合并重度NAFLD的曲线下面积(AUC)为0.856,其灵敏度、特异度和准确度分别为86.2%、79.5%和81.4%,显著高于三项指标单独评估(其AUC分别为0.744、0.752和0.704,P＜0.05)。结论 T2DM合并NAFLD患者血清网膜素和PINP水平显著降低,而RBP4水平显著升高,利用这些指标的变化规律可能能帮助临床判断合并脂肪肝的程度,值得进一步研究。

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 网膜素, 视黄醇结合蛋白4, Ⅰ型原胶原氨基端前肽, 诊断

Abstract: Objective The aim of this study was to explore the implications of serum omentin, retinol-binding protein-4 (RBP-4) and propeptide of type I procollagen (PINP) in patients with diabetes mellitus type 2 (T2DM) and non-alcoholic fatty liver diseases (NAFLD). Methods A total of 102 patients with T2DM and NAFLD (with mild steatosis in 39 cases, moderate in 34 cases and severe in 29 cases) and 98 patients with T2DM were enrolled in our hospital between June 2019 and December 2021. The hepatic steatosis was evaluated by ultrasonography, and serum omentin, RBP4 and PINP levels were detected by ELISA. The diagnostic performance was evaluated by the area under the receiver operating characteristic curve (AUC). Results Serum omentin and PINP levels in patients with T2DM and NAFLD were (45.4±12.4) ng/mL and (29.6±6.2) ng/mL, significantly lower than [(68.3±15.6) ng/mL and (35.8±7.3) ng/mL, respectively, P<0.05], while serum RBP4 level was(26.6±5.1)mg/L, significantly higher than [(20.1±4.6)mg/L, P＜0.05] in patients with T2DM; serum omentin and PINP levels in patients with severe NAFLD were (40.7±4.9)ng/mL and (25.8±3.7)ng/mL, significantly lower than [(45.2±5.6)ng/mL and (29.9±4.0)ng/mL, respectively, P＜0.05] in patients with moderate NAFLD or [(49.1±6.2)ng/mL and (32.2±3.3)ng/mL, respectively, P＜0.05] in patients with mild NAFLD, while serum RBP4 level was (30.3±3.0)mg/L, significantly higher than [(26.5±2.8)mg/L, P＜0.05] in patients with moderate NAFLD or [(23.9±3.1)mg/L, P＜0.05] in patients with mild NAFLD; the AUC was 0.856 by serum omentin, RBP4 and PINP level combination in predicting severe NAFLD in patients with T2DM and NAFLD, with the sensitivity, specificity and accuracy of 86.2%, 79.5% and 81.4%. Conclusion Serum omentin and PINP levels decrease and serum RBP4 level increase in patients with T2DM and NAFLD, which might help predicting hepatic steatosis and needs further clinical investigation.

Key words: Non-alcoholic fatty liver diseases, Type 2 diabetes mellitus, Omentin, Retinol-binding protein-4, Propeptide of type I procollagen, Diagnosis

蔡勇, 李璟, 欧琴. 2型糖尿病合并非酒精性脂肪性肝病患者血清网膜素、视黄醇结合蛋白4和Ⅰ型原胶原氨基端前肽水平及意义分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 800-803.

Cai Yong, Li Jing, Ou Qin. Implications of serum omentin, retinol-binding protein-4 and propeptide of type I procollagen in patients with diabetes mellitus type 2 and non-alcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2022, 25(6): 800-803.

参考文献

[1] Moroldo M, Munyaka PM, Lecardonnel J,et al. Integrative analysis of blood and gut microbiota data suggests a non-alcoholic fatty liver disease (NAFLD)-related disorder in French SLA minipigs. Sci Rep,2020,10(1):234.
[2] Wang S, Cai B, Han X,et al. Vitamin D supplementation for nonalcoholic fatty liver disease in type 2 diabetes mellitus: a protocol for a systematic review and meta-analysis. Medicine (Baltimore), 2020,99(19):e20148.
[3] Leylabadlo HE, Kafil HS, Farajnia S,et al. Gut microbiota in nonalcoholic fatty liver diseases with and without type-2 diabetes mellitus. Eur J Gastroenterol Hepatol,2021,33(1):548-554.
[4] Zhou Q, Wang Y, Wang J, et al. Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Medicine (Baltimore), 2021,100(10):e24940.
[5] Kalantarhormozi M, Jouyan N, Asadipooya K,et al. Evaluation of adipokines, adiponectin, visfatin, andomenntin in uncomplicated type I diabetes patients before and after treatment of diabetic ketoacidosis. J Endocrinol Invest, 2020,43(12):1723-1727.
[6] Buckner T, Shao B, Eckel RH, et al. Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes. J Clin Lipidol,2021,15(1):235-242.
[7] Nordklint AK, Almdal TP, Vestergaard P,et al. Effect ofmetformin vs. Placebo in combination with insulin analogues on bone markers P1NP and CTX in patients with type 2 diabetes mellitus. Calcif Tissue Int, 2020,107(2):160-169.
[8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018, 21(2):23-29.
[9] 中华医学会糖尿病学分会.中国2型糖尿病防治指南( 2017年版) .中华糖尿病杂志,2018,10(1) :4- 67.
[10] 中国肝病学会脂肪肝与酒精性肝病研究组.非酒精性脂肪性肝病诊疗指南.中华肝脏病杂志,2006,14(3):161-163.
[11] Cigrovski-Berkovic M, Virovic-Jukic L, Bilic-Curcic I,et al. Post-transplant diabetes mellitus and preexisting liver disease-a bidirectional relationship affecting treatment and management. World J Gastroenterol, 2020,26(21):2740-2757.
[12] Biscetti F, Nardella E, Rando MM,et al. Association betweenomentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study. Cardiovasc Diabetol, 2020,19(1):170.
[13] Montazerifar F, Bakhshipour AR, Karajibani M,et al. Serumomentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease. J Res Med Sci,2017,30(22):70.
[14] Bekaert M, Ouwens DM, Horbelt T,et al. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity. Obesity,2016,24(12):2544-2552.
[15] Izadi A, Aliasghari F, Gargari BP,et al. Strong association between serum vitamin D and vaspin levels, AIP, VAI and liver enzymes in NAFLD patients. Int J Vitam Nutr Res, 2020,90(1):59-66.
[16] Scotece M, Koskinen-Kolasa A, Pemmari A, et al. Novel adipokine associated with OA: retinol binding protein 4 (RBP4) is produced by cartilage and is correlated with MMPs in osteoarthritis patients. Inflamm Res,2020 69(4):415-421.
[17] Tsai YL, Liu CW, Huang SF,et al. Urinary fatty acid and retinol binding protein-4 predict CKD progression in severe NAFLD patients with hypertension: 4-year study with clinical and experimental approaches. Medicine,2020 99(2):e18626.
[18] T0njes A, Blüher M, Stumvoll M. Retinol-binding protein 4 and new adipocytokines in nonalcoholic fatty liver disease. Curr Pharm Des, 2010, 16(17):1921-1928.
[19] Lebedev DA, Lyasnikova EA, Vasilyeva EY,et al. Type 2 diabetes mellitus and chronic heart failure with midrange and preserved ejection fraction: a focus on serum biomarkers of fibrosis. J Diabetes Res, 2020,69(7):76153.
[20] Fan S, Wang Z, Li Q,et al. The relationship between BSP mRNA expression and 25(OH)D/OPG in peripheral blood of newly diagnosed T2DM patients with different bone mass. Endokrynol Pol, 2020,71(2):160-167.

2型糖尿病合并非酒精性脂肪性肝病患者血清网膜素、视黄醇结合蛋白4和Ⅰ型原胶原氨基端前肽水平及意义分析^*

Implications of serum omentin, retinol-binding protein-4 and propeptide of type I procollagen in patients with diabetes mellitus type 2 and non-alcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韩芳, 李佳峥, 南月敏. 肝硬化并发急性肾损伤诊治进展[J]. 实用肝脏病杂志, 2022, 25(6): 768-771.
[2]	李向阳, 丁光伟, 靳铭. 恩替卡韦治疗慢性乙型肝炎合并NAFLD患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 776-779.
[3]	孙峥, 王笑烨, 袁景, 梁丽. 达格列净联合利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 796-799.
[4]	孙凌, 杭玮, 邓国忠. 二甲双胍联合吡格列酮治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 804-807.
[5]	王玉梅, 袁向东, 刘玉玲, 赵子瑜. 提示肥胖症儿童/青少年存在非酒精性脂肪性肝炎的指标分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 808-811.
[6]	王晓华, 曾雅琳, 郭萃蓉. 非酒精性脂肪性肝病进展性肝纤维化患者空腹血糖受损和胰岛素抵抗调查^*[J]. 实用肝脏病杂志, 2022, 25(6): 812-815.
[7]	樊叶, 张喜梅, 张岩. 非酒精性脂肪性肝病患者血清胱抑素C、脂蛋白α和nesfatin-1水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(6): 816-819.
[8]	李响, 张铁英, 张旭辉, 孟繁坤. 基于超声参数的半定量评分评估乙型肝炎肝硬化食管静脉曲张价值探讨^*[J]. 实用肝脏病杂志, 2022, 25(6): 857-860.
[9]	张耀辉, 郑章增, 高星, 张亚利. 超声造影时间-强度曲线诊断肝硬化患者肝内小结节病灶价值研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 861-864.
[10]	邬政宏, 吴冬秋, 刘四斌. DCE-MRI诊断原发性肝癌效能和TACE术后评估肿瘤活性应用价值研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 881-884.
[11]	黄玮, 范智慧, 陈磊, 王丹. 脂肪肝对超声造影诊断肝内炎性假瘤的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 897-900.
[12]	沈一芃, 祝峻峰. 肝硬化并发自发性细菌性腹膜炎临床研究进展^*[J]. 实用肝脏病杂志, 2022, 25(6): 909-912.
[13]	罗楠, 李荣宽. 肝硬化并发自发性细菌性腹膜炎诊治现状[J]. 实用肝脏病杂志, 2022, 25(5): 616-619.
[14]	曾婷, 雷向阳, 白晓苏. 氧化苦参碱对非酒精性脂肪性肝病大鼠肝脏保护作用研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 624-627.
[15]	米朦, 卢秉久, 王学良, 王晓彤, 郑佳连. 代谢相关性脂肪性肝病患者血脂分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 653-656.